Celastrol

Celastrol is a pentacyclic triterpenoid that exerts anti-inflammatory and anticancer activity by inhibiting NF-κB and AP-1 signaling, disrupting the HSP90-Cdc37 chaperone complex, inducing ROS-mediated apoptosis via peroxiredoxin inhibition, and suppressing pro-inflammatory mediators including TNF-α, IL-6, iNOS, and COX-2 at concentrations as low as 0.05–1 μM in vitro. Preclinical evidence demonstrates that celastrol induces G2/M cell cycle arrest and caspase-3/7-dependent apoptosis in hepatocellular carcinoma (Huh7) cells at concentrations above 1 μM, and exerts potent antimicrobial activity against Gram-positive bacteria with MIC values of 0.16–2.5 μg/mL, though no human clinical trials with quantified effect sizes for isolated celastrol have been published.

Origin & History

Celastrol is a quinone methide triterpenoid isolated from the root bark of Tripterygium wilfordii Hook F, a woody vine native to temperate regions of China, Japan, and Korea, commonly called thunder god vine. The plant grows in mountain forests and hillside thickets, with the root bark being the primary source of pharmacologically active constituents. Celastrol has been used in traditional Chinese medicine for centuries, though modern isolation as a purified compound relies on solvent extraction and chromatographic purification techniques developed in the 20th century.

Historical & Cultural Context

Celastrol derives from Tripterygium wilfordii, a plant with a documented history in traditional Chinese medicine (TCM) spanning several centuries, where root preparations were applied to treat inflammatory arthritides, autoimmune skin disorders, and pain syndromes under TCM diagnostic frameworks. The plant is referenced in Chinese pharmacopoeial texts and was colloquially known as 'thunder god vine,' reflecting the potency and toxicity associated with its use, which demanded careful preparation and dosing by skilled practitioners. Traditional preparation involved decoction of the dried root bark or production of alcohol-based tinctures, with strict avoidance of other plant parts (leaves, flowers, stem) that carry higher acute toxicity. Modern isolation of celastrol as a discrete bioactive compound began in the mid-20th century as phytochemical fractionation techniques advanced, transitioning the compound from a component of complex herbal mixtures to a defined molecular entity of pharmacological interest.

Health Benefits

- **Anti-inflammatory Activity**: Celastrol suppresses nitric oxide, PGE₂, iNOS, COX-2, TNF-α, and IL-6 production at 0.05–1 μM in vitro by inhibiting NF-κB and AP-1 transcription factors, making it a multi-target anti-inflammatory agent relevant to conditions such as rheumatoid arthritis.
- **Anticancer Potential**: At concentrations above 1 μM, celastrol induces G2/M cell cycle arrest and caspase-3/7-mediated apoptosis in hepatocellular carcinoma Huh7 cells, with in vivo xenograft studies showing inhibition of tumor growth and migration when combined with phytohemagglutinin (PHA).
- **HSP90 Chaperone Inhibition**: Celastrol disrupts the HSP90-Cdc37 co-chaperone complex and binds directly to the C-terminal domain of HSP90α, causing protein oligomerization and impairing chaperone-dependent oncogenic client protein stabilization critical for tumor cell survival.
- **Antioxidant and ROS Modulation**: Celastrol and its derivatives inhibit peroxiredoxin (PRDX) enzymes, with optimized derivatives achieving IC₅₀ values as low as 0.042 μM for PRDX1, elevating intracellular reactive oxygen species to selectively trigger apoptosis in cancer cells while protecting normal tissue at lower doses via antioxidant mechanisms.
- **Antimicrobial Activity**: Celastrol demonstrates bactericidal activity against Gram-positive bacteria such as Bacillus subtilis with MIC values of 0.16–2.5 μg/mL by disrupting the cytoplasmic membrane (inducing potassium leakage and mesosome-like structures) and rapidly inhibiting uptake of glucose, DNA, RNA, protein, and peptidoglycan precursors by more than 70% within 2–5 minutes at 3 μg/mL.
- **Neutrophil and Innate Immune Modulation**: Celastrol suppresses neutrophil oxidative burst and neutrophil extracellular trap (NET) formation, reducing citrullinated histone markers associated with NET-driven tissue damage relevant to autoimmune and inflammatory diseases.
- **SYK/MEK/ERK Pathway Suppression**: By inhibiting SYK kinase and downstream MEK/ERK signaling alongside IκBα pathway modulation, celastrol interferes with immune cell activation cascades involved in chronic inflammatory and allergic conditions at sub-micromolar concentrations.

How It Works

Celastrol's anti-inflammatory mechanism centers on inhibition of NF-κB and AP-1 transcription factors, suppressing downstream expression of iNOS, COX-2, TNF-α, and IL-6, and blocking SYK/MEK/ERK and IκBα signaling pathways at concentrations of 0.05–1 μM. Its anticancer activity involves disruption of the HSP90-Cdc37 chaperone complex through direct binding to Cdc37 or the C-terminal domain of HSP90α, causing HSP90 oligomerization and destabilizing oncogenic client proteins, while simultaneously inducing G2/M cell cycle arrest and activating caspase-3/7-dependent apoptosis at concentrations above 1 μM. Celastrol also inhibits peroxiredoxin (PRDX) antioxidant enzymes, elevating intracellular reactive oxygen species to pro-apoptotic levels in cancer cells, with optimized celastrol derivatives demonstrating IC₅₀ values as low as 0.042 μM for PRDX1. The compound's electrophilic quinone methide core is believed to contribute to its multi-target activity through covalent modification of reactive cysteine residues in key regulatory proteins, though this reactivity also poses selectivity and cytotoxicity challenges at higher concentrations.

Scientific Research

The evidence base for celastrol is entirely preclinical, consisting of in vitro cell culture studies and in vivo rodent xenograft or inflammation models; no published randomized controlled trials isolating celastrol as a purified compound in human subjects with quantified clinical outcomes have been identified. In vitro studies have characterized concentration-response relationships in cancer cell lines (including Huh7 hepatocellular carcinoma), inflammatory macrophage and neutrophil models, and Gram-positive bacterial assays, with well-defined IC₅₀ and MIC values across multiple endpoints. Clinical use of Tripterygium wilfordii whole-plant extracts (which contain celastrol among many other constituents) has been documented in Chinese rheumatoid arthritis and skin disease populations with dose adjustments by sex, but these studies cannot be attributed to celastrol alone and generally lack the methodological rigor of controlled trials. Overall, the evidence for celastrol specifically remains at a preclinical stage, and translation to human therapeutic use requires resolution of critical challenges including poor aqueous solubility, narrow therapeutic window, and absence of validated pharmacokinetic data in humans.

Clinical Summary

No clinical trials examining isolated celastrol as a defined intervention in human subjects have been reported in the available literature, making a formal clinical summary impossible at this time. Tripterygium wilfordii plant extracts have been used in documented clinical settings for rheumatoid arthritis and inflammatory skin diseases in China, with sex-based dosing adjustments, but these preparations contain dozens of bioactive compounds beyond celastrol, preventing attribution of outcomes to any single constituent. Preclinical xenograft data demonstrate tumor growth suppression and apoptosis induction at low concentrations in combination with phytohemagglutinin, but these findings require confirmation in dose-escalation and pharmacokinetic human studies. Confidence in celastrol's clinical utility for any specific indication is currently low, and its development as a therapeutic agent depends on overcoming bioavailability, solubility, and toxicity barriers through formulation strategies such as nanoparticle encapsulation or structural derivatization.

Nutritional Profile

Celastrol is a purified bioactive triterpenoid compound and does not possess a conventional nutritional profile in terms of macronutrients, vitamins, or dietary minerals. Its molecular identity is defined by a pentacyclic lupane-type triterpenoid backbone with a quinone methide functional group at the A ring and a carboxylic acid at C-29, giving it a molecular weight of 450.6 g/mol and molecular formula C₂₉H₃₈O₄. Phytochemically, it is the most abundant bioactive triterpenoid in Tripterygium wilfordii root bark extracts, which also contain approximately 20 other triterpenoids, 46 diterpenoids (including the highly toxic triptolide), and 21 alkaloids. Bioavailability of celastrol is constrained by low aqueous solubility (precipitation above approximately 40 μg/mL), significant plasma protein binding, and likely extensive first-pass metabolism, though precise human oral bioavailability figures have not been established.

Preparation & Dosage

- **Purified Compound (Research Grade)**: Used exclusively in preclinical laboratory settings; dissolved in DMSO for in vitro studies at 0.05–10 μM; no pharmaceutical-grade oral formulation is commercially approved.
- **Traditional Whole-Plant Extract (Thunder God Vine)**: Root bark extracts of Tripterygium wilfordii are administered orally in traditional Chinese medicine for rheumatoid arthritis and skin diseases; doses in clinical practice are reported to be approximately one-third higher in men than women, though standardization to celastrol content is not established.
- **Effective In Vitro Concentrations**: Anti-inflammatory effects observed at 0.05–1 μM; apoptosis induction in cancer cells at >1 μM; antimicrobial bactericidal effects at 3–40 μg/mL (limited by solubility ceiling above 40 μg/mL).
- **Experimental Nanoformulations**: Celastrol has been encapsulated in lipid nanoparticles and polymeric micelles in preclinical studies to improve aqueous solubility and bioavailability, though none are approved for human use.
- **Standardization**: No commercial supplement is standardized to a defined celastrol percentage; whole-plant extracts vary widely in celastrol content depending on extraction method and plant part used.
- **Timing and Administration Notes**: No human pharmacokinetic data exist to guide dosing intervals; preclinical models suggest rapid cellular uptake, with antimicrobial inhibition occurring within 2–5 minutes of exposure at effective concentrations.

Synergy & Pairings

Preclinical evidence indicates that celastrol combined with phytohemagglutinin (PHA) exerts enhanced inhibition of Huh7 hepatocellular carcinoma cell growth, migration, and apoptosis induction compared to either agent alone, suggesting synergy through complementary immune-activating and direct cytotoxic mechanisms. Celastrol's inhibition of HSP90 chaperone function may potentiate the activity of kinase inhibitors or proteasome inhibitors whose oncogenic client proteins depend on HSP90 for stability, a mechanistically rational combination explored in preclinical oncology research. Its anti-inflammatory pathway targeting of NF-κB alongside COX-2 and cytokine suppression theoretically complements omega-3 fatty acids or curcumin, which also modulate eicosanoid and NF-κB pathways, though formal co-administration studies in humans have not been conducted.

Safety & Interactions

Celastrol exhibits concentration-dependent cytotoxicity in mammalian cells, with apoptosis induction occurring above 1 μM, which presents a narrow therapeutic window that limits safe dosing and is a primary obstacle to clinical development. Tripterygium wilfordii whole-plant extracts, which contain celastrol alongside highly toxic compounds such as triptolide, carry well-documented risks of hepatotoxicity, nephrotoxicity, reproductive toxicity (including male infertility and amenorrhea), gastrointestinal disturbances, and immunosuppression, although these cannot be ascribed solely to celastrol. No specific drug interaction studies for isolated celastrol in humans have been published, but given its inhibition of NF-κB, COX-2, and HSP90 pathways, theoretical interactions with immunosuppressants, NSAIDs, chemotherapy agents, and CYP450-metabolized drugs are plausible and warrant caution. Celastrol and all Tripterygium wilfordii preparations are contraindicated in pregnancy due to documented embryotoxic and teratogenic effects in animal models, and should be avoided in women of childbearing potential, patients with pre-existing hepatic or renal impairment, and individuals on concurrent immunosuppressive therapy without medical supervision.